Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sera Prognostics ( (SERA) ) has provided an update.
On January 31, 2025, Sera Prognostics updated its corporate investor presentation to reflect findings from the PRIME study, which emphasizes the significant clinical and economic challenges posed by preterm births. The company’s PreTRM test, validated for use between 18 to 20 weeks of gestation, offers a predictive assessment of preterm birth risk, potentially reducing costs associated with neonatal care. This advancement positions Sera Prognostics as a leader in addressing a crucial healthcare issue, with implications for improved neonatal outcomes and reduced healthcare expenditures.
More about Sera Prognostics
Sera Prognostics operates in the healthcare industry, specializing in predictive diagnostic tests aimed at improving pregnancy outcomes, with a focus on preterm birth risk assessment. The company’s primary product, the PreTRM test, uses proteomics to predict spontaneous preterm birth by analyzing protein markers from a blood sample.
YTD Price Performance: -20.17%
Average Trading Volume: 107,317
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $224.6M
See more data about SERA stock on TipRanks’ Stock Analysis page.